口罩股再掀漲停潮 泰達股份(000652.SZ)等繼續漲停
格隆匯2月6日丨口罩股今日延續走強,再升科技、嘉麟傑、泰達股份、道恩股份、南衞股份、振德醫療、奧美醫療、陽普醫療、尚榮醫療等10餘股封板。據悉,口罩和醫用防護服是此次疫情中需求最為激增的兩大產品,也是疫情較重的地區所急需。根據當前疫情實際情況以及政府公佈情況,目前口罩和醫用防護服依然存在亟待解決的需求缺口,相關部門正在積極推動具備條件的廠家轉化、擴大口罩和醫用防護服產能,以政府統一採購、調撥的形式支持防疫大局。改委社會發展司副司長昨日表示,全國口罩日產量已達到1480萬隻,產能利用率67%,N95口罩11.6萬隻,其他醫用998萬隻。再次重申,疫情過後富餘產量,只要符合標準,國家將收儲。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.